Moderna Inc (BSP:M1RN34)
R$ 38.38 +1.38 (+3.73%) Market Cap: 306.45 Bil Enterprise Value: 286.73 Bil PE Ratio: 0 PB Ratio: 8.82 GF Score: 55/100

Moderna, Inc. at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2026 / 02:00PM GMT
Release Date Price: R$38.38 (+3.73%)
Terence Flynn
Morgan Stanley & Co Ltd - Analyst

Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's US biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Very pleased to be hosting Moderna this morning. From the company, we have Stephen Hoge, the company's President. Stephen, thanks so much for being here. Really enjoy an opportunity to get to speak with you today.

Questions & Answers

Terence Flynn
Morgan Stanley & Co Ltd - Analyst

I guess, first, what I wanted to start off with is INT program is front and center. Congratulations on the positive Phase III adjuvant melanoma data. So maybe just talk to us about implications of that data for the broader strategy at Moderna in terms of what does mean for additional indications. What does this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot